newsfilter
← Latest News
Business Wire·

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

  • Alkermes plc (NASDAQ: ALKS) appointed Anne C. Whitaker as a new independent director to its Board of Directors.
  • Whitaker is a seasoned biopharmaceutical executive with prior CEO roles at Aerami Therapeutics, Novoclem Therapeutics, & Synta Pharmaceuticals.
  • She previously held senior commercial & executive positions at Bausch Heath, Sanofi, & GlaxoSmithKline.
  • Whitaker currently serves on the boards of Basilea Pharmaceutica, ICON plc, QurAlis LLC, Bespak, Beaconcure Technologies, & Trinity Partners.
  • She holds a B.S. in chemistry with a minor in business administration from the University of North Alabama.
  • CEO Blair Jackson stated Whitaker's experience will support Alkermes' strategy to advance its neuroscience pipeline & drive growth.
  • Board Chairman Richard Pops noted her unique perspective on key decisions for long-term industry success.
  • Alkermes develops innovative medicines for neuroscience, including proprietary products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, & narcolepsy.
  • The company's pipeline includes late-stage candidates for narcolepsy & idiopathic hypersomnia, plus early-stage orexin 2 receptor agonists for ADHD & fatigue associated with multiple sclerosis & Parkinson's disease.
  • Alkermes is headquartered in Ireland with offices & R&D in Massachusetts & a manufacturing facility in Ohio.